Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Pieters

Showing results (271-280 of 336) with videos related to

Pageof 34
Sort By:
Blood|January 4, 2008
Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosisBrian V Balgobind, Pieter Van Vlierberghe, Ans M W van den Ouweland, et al.
Haematologica|March 3, 2017
Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patientsSebastiaan D T Sassen, Ron A A Mathôt, Rob Pieters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2011
Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemiaMariël L te Winkel, Rob Pieters, Wim C J Hop, et al.
Genes, Chromosomes & Cancer|November 7, 2015
The clinical phenotype of YWHAE-NUTM2B/E positive pediatric clear cell sarcoma of the kidneySaskia L Gooskens, Colin Kenny, Antonio Lazaro, et al.
Blood|January 28, 2009
Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemiaIris H I M Hollink, Marry M van den Heuvel-Eibrink, Martin Zimmermann, et al.
British Journal of Haematology|December 2, 2017
A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in childrenRosemary Sutton, Nicola C Venn, Tamara Law, et al.
Haematologica|September 8, 2006
The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocolsMartine van Grotel, Jules P P Meijerink, H Berna Beverloo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]Deepa Bhojwani, Huining Kang, Renee X Menezes, et al.
Bone|November 30, 2013
Bone mineral density at diagnosis determines fracture rate in children with acute lymphoblastic leukemia treated according to the DCOG-ALL9 protocolMariël L te Winkel, Rob Pieters, Wim C J Hop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemiaKjeld Schmiegelow, Mette Frandsen Levinsen, Andishe Attarbaschi, et al.
Pageof 34

Showing results (271-280 of 336) with videos related to

Sort By:
Pageof 34
Blood|January 4, 2008
Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosisBrian V Balgobind, Pieter Van Vlierberghe, Ans M W van den Ouweland, et al.
Haematologica|March 3, 2017
Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patientsSebastiaan D T Sassen, Ron A A Mathôt, Rob Pieters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2011
Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemiaMariël L te Winkel, Rob Pieters, Wim C J Hop, et al.
Genes, Chromosomes & Cancer|November 7, 2015
The clinical phenotype of YWHAE-NUTM2B/E positive pediatric clear cell sarcoma of the kidneySaskia L Gooskens, Colin Kenny, Antonio Lazaro, et al.
Blood|January 28, 2009
Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemiaIris H I M Hollink, Marry M van den Heuvel-Eibrink, Martin Zimmermann, et al.
British Journal of Haematology|December 2, 2017
A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in childrenRosemary Sutton, Nicola C Venn, Tamara Law, et al.
Haematologica|September 8, 2006
The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocolsMartine van Grotel, Jules P P Meijerink, H Berna Beverloo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]Deepa Bhojwani, Huining Kang, Renee X Menezes, et al.
Bone|November 30, 2013
Bone mineral density at diagnosis determines fracture rate in children with acute lymphoblastic leukemia treated according to the DCOG-ALL9 protocolMariël L te Winkel, Rob Pieters, Wim C J Hop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemiaKjeld Schmiegelow, Mette Frandsen Levinsen, Andishe Attarbaschi, et al.
Pageof 34